GlassScriptPhysician profile
Seth Ryan Anderson
NPI 1003290263
$3,330.42
in general payments reported to CMS, 2019-2025
35 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $732 · 2023: $652 · 2024: $841 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $405.10 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.27 | 2021-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $325.90 | 2022-2025 | Airsupra, Imfinzi, Tezspire |
| Regeneron Healthcare Solutions, INC. | $257.71 | 2021-2025 | Dupixent |
| United Therapeutics Corporation | $226.20 | 2022-2025 | Tyvaso, Tyvaso |
| Gilead Sciences, INC. | $173.63 | 2021-2024 | Veklury |
| Merck Sharp & Dohme LLC | $158.35 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $156.37 | 2022-2025 | Glassia, Hyqvia |
| Mallinckrodt Hospital Products INC. | $129.71 | 2021-2025 | Acthar |
| Vifor Pharma, INC. | $113.80 | 2024-2025 | Veltassa, Zemaira |
| Genzyme Corporation | $113.20 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $99.32 | 2021-2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $98.99 | 2021-2023 | Yupelri |
| Baxter Healthcare | $89.45 | 2022-2024 | Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $56.81 | 2023-2025 | Arikayce |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $54.12 | 2021-2024 | Smartvest |
| Shionogi INC | $52.78 | 2021-2023 | Fetroja |
| Pfizer INC. | $51.82 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $47.79 | 2021-2022 | |
| Verona Pharma, INC. | $47.26 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $44.33 | 2025 | Yupelri |
| Abiomed | $38.04 | 2024 | Impella |
| Ani Pharmaceuticals, INC. | $36.17 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $26.04 | 2024 | Lumryz |
| Tactile Systems Technology INC | $19.96 | 2022 | |
| La Jolla Pharmaceutical Company | $19.44 | 2021 | |
| Pulmonx Corporation | $18.46 | 2021 | |
| Axsome Therapeutics, INC. | $17.88 | 2022 | |
| Csl Behring | $17.85 | 2024 | Hizentra |
| Alexion Pharmaceuticals, INC. | $15.56 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.53 | 2021 | |
| Philips North America LLC | $14.44 | 2024 | (Ak6) Vest Therapy |
| Advanced Respiratory, INC | $13.89 | 2021 | |
| Phadia US INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.